Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. Stock

Equities

874

CNE100000387

Pharmaceuticals

Market Closed - Hong Kong S.E. 04:08:20 2024-05-14 am EDT 5-day change 1st Jan Change
23.05 HKD +0.22% Intraday chart for Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. +5.25% +5.98%
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site

Financials

Sales 2024 * 80.44B 11.12B 86.89B Sales 2025 * 85.61B 11.84B 92.47B Capitalization 51.17B 7.08B 55.27B
Net income 2024 * 4.17B 577M 4.51B Net income 2025 * 4.44B 613M 4.79B EV / Sales 2024 * 0.4 x
Net cash position 2024 * 19.18B 2.65B 20.71B Net cash position 2025 * 22.46B 3.11B 24.26B EV / Sales 2025 * 0.34 x
P/E ratio 2024 *
8.57 x
P/E ratio 2025 *
8.24 x
Employees 28,048
Yield 2024 *
-
Yield 2025 *
4%
Free-Float 49.33%
More Fundamentals * Assessed data
Dynamic Chart
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Baiyunshan Pharmaceutical's 2023 Profit Rises 2% MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Announces Final Ordinary Dividend for the Year Ended 31 December 2023 CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Baiyunshan Pharma's Unit Gets Green Light to Produce Hepatitis B Drug MT
Guangzhou Pharma Unit Gets Green Light to Trial Oral Liquid Drug MT
Guangzhou Baiyunshan Pharmaceutical Arm Floats 1 Billion Yuan Biomedical VC Fund MT
Guangzhou Baiyunshan Pharmaceutical Ends Spin-Off Plans, Seeks China Listing for Subsidiary MT
Guangzhou Pharma Expands Scope of Drug Production License MT
Guangzhou Baiyunshan Pharmaceutical's Profit Up 11% in Q3 MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Baiyunshan Pharmaceutical Reports Increase in H1 Attributable Profit MT
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(SHSE:600332) added to Shanghai Stock Exchange 180 Value Index CI
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited(SHSE:600332) added to SSE 180 Index CI
More news
1 day+0.22%
1 week+5.25%
Current month+10.29%
1 month+19.18%
3 months+14.68%
6 months+11.89%
Current year+5.98%
More quotes
1 week
21.20
Extreme 21.2
23.30
1 month
19.40
Extreme 19.4
23.30
Current year
18.48
Extreme 18.48
23.30
1 year
18.48
Extreme 18.48
27.70
3 years
16.56
Extreme 16.56
27.70
5 years
16.56
Extreme 16.56
37.35
10 years
15.60
Extreme 15.6
42.50
More quotes
Managers TitleAgeSince
Chief Executive Officer 57 17-06-22
Chairman 57 -
Director/Board Member 47 14-12-31
Members of the board TitleAgeSince
Director/Board Member 76 10-06-27
Chairman 58 10-06-27
Director/Board Member 58 10-06-27
More insiders
Date Price Change Volume
24-05-14 23.05 +0.22% 1 482 000
24-05-13 23 +0.88% 992,690
24-05-10 22.8 +4.11% 1,470,000
24-05-09 21.9 +2.10% 680,206
24-05-08 21.45 -0.92% 994,261

Delayed Quote Hong Kong S.E., May 14, 2024 at 04:08 am EDT

More quotes
Guangzhou Baiyunshan Pharmaceutical Holding Co., Ltd. specializes in researching, developing and manufacturing pharmaceutical products. The group's products include analgesics, antibiotics, medicines for the treatment of stomach disorders, treatment of cough, antitoxic products, etc.
Calendar
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
21.34 CNY
Average target price
22.1 CNY
Spread / Average Target
+3.55%
Consensus

Quarterly revenue - Rate of surprise

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW